Zheng Quan Shi Bao Wang·2025-07-10 03:16Core Insights - Jiangsu Province has 16 companies listed in the 2024 China Pharmaceutical Industry Top 100, an increase of one from the previous year, maintaining the highest number in the country for two consecutive years [1][2] - The province's biopharmaceutical cluster achieved over 450 billion yuan in revenue and over 73 billion yuan in profit, both ranking first in the nation [1] - Jiangsu's chemical drug sector surpassed 200 billion yuan, while the medical device sector exceeded 100 billion yuan [1] Industry Overview - The top 100 companies reflect the concentrated development of the pharmaceutical industry in Jiangsu, which has established a solid foundation and competitive advantage nationally [2] - The province has cultivated 8 national manufacturing single champion enterprises and 214 national specialized and innovative "little giant" enterprises [1] - Jiangsu's focus on collaborative innovation and support for innovative drug and medical device development is evident through policies that integrate resources from universities, research platforms, and hospitals [1][2] Company Performance - Among the listed companies, 9 are in the top 50, with Heng Rui Medicine and Zhengda Tianqing Pharmaceutical ranking 8th and 9th respectively [2] - Companies such as Innovent Biologics and Hansoh Pharmaceutical have made significant jumps in rankings, moving up 8 and 5 places respectively [2] - Jiangsu has 5 companies in the top 10 for "2024 R&D Intensity Industrial Enterprises," with Innovent Biologics leading the list [2] Future Outlook - The Jiangsu Provincial Industry and Information Technology Department plans to enhance the "1650" industrial system, focusing on platform synergy, mechanism empowerment, and ecological cultivation [2] - The goal is to strengthen inter-departmental collaboration, improve policy support systems, and accelerate the creation of a biopharmaceutical cluster with international competitiveness [2]